ALK and adenocarcinoma: Fusions involving the rearranged during transfection proto-oncogene (RET) occur in 1–2% of NSCLC [5,6,7], and are more commonly seen in patients with minimal to no smoking history and adenocarcinoma histologic subtype, reminiscent of ALK and ROS1 fusions [8,9,10,11].